SCHEMBL23993440

SCHEMBL23993440

COc1ncc(-c2cc([C@H]3C[C@@H]3c3ccc(OC(F)F)cc3)c3nccn3n2)c(OC)n1

nearest known ligand 0.33

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ MDM2 Q00987 7/20 0.33
▸ PPARD Q03181 1/20 0.33
▸ PDE10A Q9Y233 2/20 0.32
▸ MAT2A P31153 3/20 0.32
▸ CSF1R P07333 1/20 0.32
▸ MTOR P42345 2/20 0.31
▸ TP53 P04637 5/20 0.31
▸ SYK P43405 1/20 0.31
▸ PIK3CD O00329 1/20 0.30
▸ ABL1 P00519 1/20 0.30
▸ EGFR P00533 1/20 0.30
▸ HCK P08631 1/20 0.30
▸ SRC P12931 1/20 0.30
▸ PIK3CA P42336 1/20 0.30
▸ PIK3CB P42338 1/20 0.30
▸ PIK3CG P48736 1/20 0.30
▸ EPHB4 P54760 1/20 0.30
▸ PRKDC P78527 1/20 0.30
▸ PI4KB Q9UBF8 1/20 0.30
▸ RXRA P19793 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL23993442 1.00 MDM2 (0.33) MDM2PPARDPDE10AMAT2ACSF1R
SCHEMBL25005516 0.91 PDE10A (0.39) PPARDPDE10AMTOR
SCHEMBL30224368 0.91 PDE10A (0.39) PPARDPDE10AMTOR
SCHEMBL23993471 0.91 PPARD (0.34) MDM2PPARDPDE10AMTORTP53
SCHEMBL23993474 0.91 PPARD (0.34) MDM2PPARDPDE10AMTORTP53
SCHEMBL30224254 0.90 CSF1R (0.34) MDM2CSF1RMTORTP53SYK
SCHEMBL25005791 0.90 CSF1R (0.34) MDM2CSF1RMTORTP53SYK
SCHEMBL23994491 0.90 MDM2 (0.34) MDM2PPARDMTORTP53SYK
SCHEMBL30182093 0.90 MDM2 (0.34) MDM2PPARDMTORTP53SYK
SCHEMBL23993110 0.88 ABL1 (0.34) MDM2PPARDMTORSYKABL1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4143194-A1 CD73 INHIBITING 2,4-DIOXOPYRIMIDINE COMPOUNDS GILEAD SCIENCES, INC. (US) 2023-03-08 — — EP disclosed
US-20230039553-A1 CD73 COMPOUNDS GILEAD SCIENCES, INC. 2023-02-09 — — US disclosed
US-20230039553-A1 CD73 COMPOUNDS GILEAD SCIENCES, INC. 2023-02-09 — — US disclosed
WO-2021222522-A1 CD73 INHIBITING 2,4-DIOXOPYRIMIDINE COMPOUNDS GILEAD SCIENCES, INC. (US) 2021-11-04 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230039553-A1 CD73 COMPOUNDS ENTPD5, ENTPD1, NT5E MDM2 2083/4885PPARD 2945/4885PDE10A 484/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback